The new coronavirus and antibody BI 767551 entered the clinical trial stage

Currently, viral meso-antibodies are being studied for treatment options for moderate or severe infections, as well as as preventive medicines for non-infected persons with a high risk of infection or potentially serious consequences.
delivers BI 767551 directly to the lungs by inhalation, which is expected to make the drug work quickly and prevent viral infections in the respiratory tract.
new antibody BI 767551 was derived from blood samples from patients with neo-corona pneumonia at the University Hospital of Cologne, tested for new coronavirus at the University of Marburg, and further developed in collaboration with Bollinger Ingeham.
the clinical study will be led by Professor Florian Klein and Professor Gerd Fätkenheuer of the University Hospital of Cologne, who will provide the antibody.
1 / 2a trials (NCT04631705 and NCT04631666) will evaluate the safety of antibodies, pharmacological characteristics and antiviral activity.
phase 1 clinical trial, antibodies were given to participants through a single infusion or single inhalation.
antibody tolerance is good, a post-validation test will be conducted.
note: There are deletions in the original text